
Crucible Therapeutics spins out with £5m
Crucible Therapeutics Ltd., the newly launched spinout company from the University of Sheffield, secured the investment of £5m from Northern...

microRNA could offer a safe target in atherosclerosis
The researcher demonstrateded that targeting of miR-206-3p with an experimental compound safely reversed the onset of atherosclerosis in a...

SpliceBio has made up a US $216m alliance with Spark Therapeutics
Under a globally exclusive licence option agreement with Roche AG, SpliceBio secures an upfront payment, opt-in and milestone payments up to $216m...

French team BioAroma awarded with BISC-E 2023 prize
In front of around 200 invited guests, the French team received the cash prize for first place in the BISC-E 2023 competition and a one-year free BIC...

ViaNautis Bio Ltd closes US$25m Series A financing
The US$25m round of cambridge-based ViaNautis Bio Ltd, founded in 2018 as SomaServe, was led 4BIO Capital, BGF (both UK), and UCB Ventures (UK, US,...

Synbio experts develop cells that hear
Swiss researchers headed by synbio expert Martin Fussenegger have equipped designer cells with a bacterail ion channel that is responsive to...

SeaBeLife secures €1.2m in funding
SeaBeLife SAS has secured €1.2m in funding, aiming to develop unique drug candidates that block cell necrosis and target two regulated cell death...